Bimatoprost vs Latanoprost: Differences, Uses, & Side Effects

Bimatoprost and latanoprost belong to the same drug class and both lower eye pressure by increasing fluid drainage from the eye, but they differ in how much redness they cause, how strongly they reduce pressure, and how they affect the tissue around your eyes over time. Both are prostaglandin analogs prescribed primarily for open-angle glaucoma and ocular hypertension, and both are dosed once daily in the evening. The practical decision between them often comes down to a tradeoff between slightly greater pressure-lowering power with bimatoprost and a milder side-effect profile with latanoprost.

How They Lower Eye Pressure

A crossover study in healthy volunteers found that bimatoprost, latanoprost, and a third prostaglandin analog (travoprost) share a similar mechanism: all three reduce intraocular pressure (IOP) without meaningfully slowing the production of fluid inside the eye. Instead, they increase the outflow of that fluid, either through the pressure-sensitive drainage route or through an alternative pathway behind the iris.¹ In simple terms, the eye constantly produces a watery fluid that nourishes its internal structures. Pressure builds when that fluid cannot drain fast enough. Both drugs essentially widen the exit channels so fluid leaves more freely.

Despite years of debate about whether bimatoprost acts through a slightly different receptor pathway than latanoprost, the functional result in living tissue looks very similar. The differences that matter to you as a patient show up not in the drainage mechanism itself but in how potent the pressure drop is and what other tissues the drug affects along the way.

Pressure-Lowering Strength

Across head-to-head trials, bimatoprost consistently edges out latanoprost in raw IOP reduction. A review of parallel-group comparison trials reported that bimatoprost produced lower mean IOP at 92% of all measurement time points, with between-group differences ranging from 0 to 1.5 mmHg.² That may sound tiny, but even a 1 mmHg change has been associated with a measurable reduction in the risk of glaucoma progression in landmark trials.

A meta-analysis pooling 13 randomized controlled trials confirmed the pattern. Morning IOP reductions were about 2.5% greater with bimatoprost at one and three months, and the gap widened to roughly 5.6% at six months. A greater proportion of bimatoprost patients also hit their target pressure at every time point, with a statistically significant difference at three months.³ These are averages, of course. Some people respond better to latanoprost, and others see no meaningful difference. But as a population-level trend, bimatoprost has a modest efficacy advantage.

Eye Redness

The most visible difference between the two drugs is conjunctival hyperemia, the medical term for bloodshot-looking eyes. Bimatoprost causes noticeably more redness than latanoprost in nearly every comparison. A short-term dosing study in healthy volunteers found that latanoprost produced the lowest hyperemia scores of the three prostaglandin analogs tested, and subjects on latanoprost were less likely to report that other people noticed their red eyes.⁴

There is an interesting wrinkle for people switching from one drug to the other. When bimatoprost was given to patients who had never used a prostaglandin analog before, hyperemia scores jumped sharply. But in patients who had previously used latanoprost and were switching to bimatoprost, the increase was much smaller.⁵ The eye surface seems to develop some tolerance to prostaglandin-related redness, so a switch may not be as dramatic as starting fresh. Still, if cosmetic appearance matters to you, latanoprost has a consistent edge here.

Changes Around the Eyes

Beyond redness, long-term prostaglandin analog use can reshape the tissue surrounding the eye, a phenomenon sometimes called prostaglandin-associated periorbitopathy. The most noticeable change is deepening of the upper eyelid sulcus (DUES), which gives the eye a slightly sunken or hollow look. This happens because prostaglandin analogs shrink the orbital fat pad behind the eyelid.

Bimatoprost causes this more frequently and more severely than latanoprost. In one study following patients switched from latanoprost to bimatoprost, 60% developed visible upper eyelid sulcus deepening within six months. The effect was more common in older patients and in non-myopic eyes.⁶ A comparative study across all three major prostaglandin analogs found periorbitopathy in about 93% of bimatoprost users, 70% of travoprost users, and 41% of latanoprost users. Specific sulcus deepening was seen in 80% of the bimatoprost group versus roughly 16% with latanoprost.⁷

The underlying explanation involves actual changes to fat tissue. A histological study measured adipocyte (fat cell) density in upper eyelid tissue and found that bimatoprost users had significantly higher cell density than untreated controls, consistent with fat cell shrinkage and compaction, while latanoprost users showed no significant difference from untreated tissue.⁸ If you use these drops only in one eye, the asymmetry can become quite conspicuous. This is one reason doctors sometimes switch patients with obvious periorbital changes from bimatoprost to latanoprost.

Iris and Skin Pigmentation

Both drugs can permanently darken the color of your iris, particularly if your eyes are a mixed color like hazel or green-brown. The melanocytes in the iris respond to prostaglandin stimulation by producing more pigment. In a study tracking latanoprost-treated eyes, about 70% of patients with mixed-color irides developed a visible color change, appearing as either a granular speckled darkening or a more diffuse deepening of the iris hue.⁹ Bimatoprost carries the same risk. If you have uniformly dark brown eyes, the change is less noticeable; if you have purely blue or gray eyes, the risk is lower because there is less mixed pigment to activate.

Both drugs also darken the skin of the eyelids and can increase pigmentation and thickness of eyelashes. These effects are generally reversible after discontinuation, unlike iris color changes, which tend to be permanent. For people using the drops in only one eye, the resulting difference in eyelash length and lid color between the two sides can be cosmetically bothersome.

Preservatives and Ocular Surface Health

Many glaucoma patients use drops for decades, and the preservatives in those drops can accumulate damage on the eye surface over time. The most common preservative, benzalkonium chloride (BAK), is known to be toxic to the surface cells of the cornea and conjunctiva. Latanoprost formulations almost universally contain BAK. Bimatoprost is available in both a BAK-preserved version and a preservative-free version (marketed in some regions as Lumigan preservative-free).

A randomized study directly comparing BAK-containing latanoprost against preservative-free bimatoprost found that both reduced IOP effectively, though latanoprost achieved a slightly greater reduction in that particular trial. However, latanoprost use was associated with reduced tear flow and a marginal increase in the area of unstable tear film at four months. The bimatoprost group had worse hyperemia, as expected, but the preservative-free formulation appeared gentler on the tear film.¹⁰ For patients with dry eye, blepharitis, or other surface problems, the preservative question can matter as much as the active ingredient. If your eyes are sensitive to BAK, a preservative-free bimatoprost formulation may be a worthwhile choice even if it causes slightly more redness.

When Switching From Latanoprost to Bimatoprost Helps

Not everyone responds well to their first prostaglandin analog. If latanoprost is not bringing your pressure down enough on its own, switching to bimatoprost is a common next step. A study of patients with normal-tension glaucoma who were not reaching their target on latanoprost found that switching to bimatoprost produced significantly greater IOP reductions at 12 weeks.¹¹

Another study compared two strategies for latanoprost non-responders: switching to bimatoprost alone or adding a second drug (brinzolamide) on top of latanoprost. About half the patients in the bimatoprost-switch group achieved a clinically meaningful IOP reduction of 2 mmHg or more.¹² The combination approach worked in a similar proportion. For doctors, this means that switching prostaglandin analogs is a reasonable first move before stacking multiple drugs, especially since adding a second bottle to the daily routine often hurts adherence.

Eyelash Growth and Cosmetic Use

One of bimatoprost’s most widely recognized side effects turned into a standalone product. The FDA approved bimatoprost 0.03% solution (marketed as Latisse) specifically for growing longer, thicker, and darker eyelashes in people with eyelash hypotrichosis. The formulation is identical to the glaucoma drop; only the applicator and labeling differ.¹³ The mechanism likely involves pushing resting hair follicles into their active growth phase and extending that phase so lashes grow longer before falling out.

Latanoprost also stimulates eyelash growth, and some doctors have prescribed it off-label for the same cosmetic purpose. However, it has never received a dedicated regulatory approval for lash enhancement, and the degree of lash growth appears somewhat less pronounced than with bimatoprost in clinical observation. The cosmetic side effect is worth knowing about even if you are only using these drops for glaucoma, because asymmetric lash growth between the treated eye and the untreated eye can be noticeable.

Beyond eyelashes, researchers have explored whether bimatoprost could help with scalp hair loss. Early investigations suggest it can produce measurable hair growth within one to two months when applied topically, though results for female pattern hair loss have been disappointing so far. Scalp applications remain experimental and off-label.¹⁴

Cost and Value Differences

When bimatoprost and latanoprost were both brand-name products, their list prices were similar. A cost-effectiveness analysis estimated nearly identical annual drug costs but found bimatoprost more cost-effective because a larger share of patients hit their target IOP without needing add-on medications.¹⁵ A separate model estimated that the cost per successful treatment outcome was roughly $568 less per patient per year with bimatoprost, even after accounting for patients who dropped out due to side effects.¹⁶

The picture is more complicated outside the United States. A European analysis spanning five countries found that the cheapest strategy in most countries was actually starting with timolol (a beta-blocker drop) and adding bimatoprost only if needed, rather than starting with either prostaglandin analog first.¹⁷ Today, generic versions of both latanoprost and bimatoprost are widely available, and latanoprost generics tend to be less expensive. Your out-of-pocket cost will depend heavily on your insurance formulary and whether your plan favors one generic over the other.

Rarer Risks Worth Knowing About

Prostaglandin analogs as a class carry a small risk of triggering inflammation inside the eye and swelling at the center of the retina. A study of latanoprost-treated patients found that about 6% developed anterior uveitis (inflammation in the front chamber of the eye), and about 2% developed cystoid macular edema (fluid buildup in the central retina).¹⁸ These complications are more common in eyes that have had previous surgery, particularly cataract extraction. A case report documented cystoid macular edema developing in a patient who had been stable on latanoprost but developed the complication after switching to bimatoprost, suggesting that the bimatoprost may have been a stronger inflammatory trigger in that individual eye.¹⁹ Both drugs are used cautiously in patients with active intraocular inflammation or a history of it.

Systemic side effects are uncommon with eye drops because very little drug reaches the bloodstream, but they are not zero. A large pharmacovigilance review analyzing over 30,000 adverse event reports found that the most common systemic reactions to prostaglandin analogs as a class were hypersensitivity reactions. Beyond that, the two drugs diverged somewhat: latanoprost was more commonly linked to cardiovascular complaints like chest pain and rapid heart rate, while bimatoprost was more often associated with skin-related reports.²⁰ These are uncommon enough that they rarely drive the choice between the two drugs, but they are worth mentioning to your doctor if you develop new systemic symptoms after starting either one.

The Bimatoprost Sustained-Release Implant

One of the biggest practical problems with glaucoma drops is that people forget to use them. Missing doses lets pressure creep back up, and over the long run, inconsistent use worsens outcomes. This is where bimatoprost has a unique advantage: it is available as a tiny biodegradable implant that is placed directly inside the eye during a brief office procedure and slowly releases medication over months.

In a dose-ranging study, higher-dose implants produced IOP reductions that actually exceeded what topical bimatoprost drops could achieve. Interestingly, the topical drop showed a U-shaped dose-response curve, meaning that increasing the concentration beyond a certain point actually reduced its effectiveness. The implant did not have this ceiling and kept performing better at higher doses.²¹ A real-world prospective study following patients for 18 months found that about 78% of eyes still had not needed any additional treatment at the end of the follow-up period. The average number of daily topical medications patients were using dropped from about 1.8 before the implant to roughly 1.0 a year later.²² The most common side effects of the implant were temporary IOP spikes and dry eye. There is no equivalent sustained-release product for latanoprost on the market at present, making this a genuine differentiator for patients who struggle with daily drop adherence.

How Doctors Typically Choose Between the Two

In practice, the choice often starts with latanoprost. It has been on the market longer, its generic versions are widely available and inexpensive, it causes less redness, and its effect on the periorbital fat is milder. For a newly diagnosed patient with moderate pressure elevation and no complicating factors, latanoprost is a sensible first try. If the pressure response is insufficient after a few months, switching to bimatoprost is one of the standard next moves, and a meaningful proportion of latanoprost non-responders will get additional pressure reduction from that switch.

Bimatoprost tends to be considered earlier in patients who need aggressive IOP lowering, such as those with advanced glaucoma or pressures that are far from target. Its slightly greater average efficacy and the availability of a sustained-release implant give it particular value in patients who have trouble with daily adherence or who need every fraction of a millimeter of mercury they can get. Cosmetic concerns sometimes steer the decision the other way, particularly for younger patients or those being treated in only one eye, where asymmetric periorbital fat loss and lash growth would be obvious.

Neither drug is clearly “better” in the abstract. They sit on a sliding scale between efficacy and tolerability, with bimatoprost tilted toward stronger pressure lowering and latanoprost tilted toward fewer visible side effects. Your doctor’s recommendation will factor in your baseline pressure, how much reduction you need, whether you have dry eye or surface disease, whether you are using the drop in one eye or both, and how sensitive you are to the cosmetic changes these drugs produce.